361 Capital LLC Purchases Shares of 38,202 Chemours Company (The) (CC)

361 Capital LLC purchased a new stake in Chemours Company (The) (NYSE:CC) during the third quarter, according to the company in its most recent filing with the SEC. The firm purchased 38,202 shares of the specialty chemicals company’s stock, valued at approximately $1,933,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. FMR LLC lifted its holdings in shares of Chemours Company (The) by 6.1% during the 2nd quarter. FMR LLC now owns 15,830,411 shares of the specialty chemicals company’s stock valued at $600,289,000 after acquiring an additional 905,038 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Chemours Company (The) by 10.3% during the 2nd quarter. Renaissance Technologies LLC now owns 3,342,200 shares of the specialty chemicals company’s stock valued at $126,736,000 after acquiring an additional 310,800 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Chemours Company (The) by 7.9% during the 3rd quarter. Bank of New York Mellon Corp now owns 2,371,909 shares of the specialty chemicals company’s stock valued at $120,042,000 after acquiring an additional 173,523 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Chemours Company (The) by 10.5% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,966,582 shares of the specialty chemicals company’s stock valued at $74,573,000 after acquiring an additional 186,228 shares in the last quarter. Finally, TIAA CREF Investment Management LLC lifted its holdings in shares of Chemours Company (The) by 126.5% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 1,789,112 shares of the specialty chemicals company’s stock valued at $67,843,000 after acquiring an additional 999,380 shares in the last quarter. Institutional investors own 72.90% of the company’s stock.

In related news, SVP David C. Shelton sold 5,908 shares of the business’s stock in a transaction dated Friday, October 13th. The shares were sold at an average price of $56.01, for a total transaction of $330,907.08. Following the completion of the sale, the senior vice president now owns 47,356 shares of the company’s stock, valued at approximately $2,652,409.56. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider E Bryan Snell sold 11,878 shares of the business’s stock in a transaction dated Monday, November 6th. The shares were sold at an average price of $53.25, for a total transaction of $632,503.50. Following the sale, the insider now directly owns 63,063 shares of the company’s stock, valued at approximately $3,358,104.75. The disclosure for this sale can be found here. Insiders sold a total of 76,520 shares of company stock valued at $4,008,293 in the last three months. Insiders own 1.14% of the company’s stock.

Several research firms recently issued reports on CC. Citigroup Inc. lifted their price target on shares of Chemours Company (The) from $45.00 to $59.00 and gave the stock a “buy” rating in a research note on Friday, August 4th. Zacks Investment Research downgraded shares of Chemours Company (The) from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 18th. UBS AG lifted their price target on shares of Chemours Company (The) from $50.00 to $59.00 and gave the stock a “neutral” rating in a research note on Friday, November 3rd. J P Morgan Chase & Co lifted their price target on shares of Chemours Company (The) to $55.00 and gave the stock an “overweight” rating in a research note on Friday, August 4th. Finally, Barclays PLC lifted their price target on shares of Chemours Company (The) from $55.00 to $58.00 and gave the stock an “overweight” rating in a research note on Monday, November 6th. One research analyst has rated the stock with a hold rating and ten have given a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $53.89.

Chemours Company (CC) traded up $0.98 on Friday, hitting $52.50. 5,089,829 shares of the stock traded hands, compared to its average volume of 2,626,603. The company has a market cap of $9,721.06, a P/E ratio of 18.62, a P/E/G ratio of 0.91 and a beta of 3.59. Chemours Company has a one year low of $20.76 and a one year high of $58.08. The company has a debt-to-equity ratio of 5.07, a current ratio of 2.19 and a quick ratio of 1.63.

Chemours Company (The) (NYSE:CC) last released its earnings results on Thursday, November 2nd. The specialty chemicals company reported $1.12 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.01 by $0.11. The company had revenue of $1.58 billion during the quarter, compared to the consensus estimate of $1.59 billion. Chemours Company (The) had a net margin of 4.86% and a return on equity of 116.80%. The company’s revenue was up 13.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.61 EPS. sell-side analysts expect that Chemours Company will post 3.73 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, December 15th. Stockholders of record on Monday, November 20th will be given a $0.03 dividend. This represents a $0.12 annualized dividend and a dividend yield of 0.23%. The ex-dividend date of this dividend is Friday, November 17th. Chemours Company (The)’s payout ratio is currently 8.28%.

ILLEGAL ACTIVITY WARNING: “361 Capital LLC Purchases Shares of 38,202 Chemours Company (The) (CC)” was first reported by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this news story on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this news story can be viewed at https://stocknewstimes.com/2017/11/19/361-capital-llc-purchases-shares-of-38202-chemours-company-the-cc.html.

About Chemours Company (The)

The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.

Institutional Ownership by Quarter for Chemours Company (The) (NYSE:CC)

Receive News & Ratings for Chemours Company (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours Company (The) and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply